Morgan Stanley previews the Mounjaro SURMOUNT-2 Ph3 from Eli Lilly (LLY)
Tweet Send to a Friend
Morgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $444.00 price target on Eli Lilly (NYSE: LLY)."We expect data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
